Dermatol. praxi. 2017;11(4):170-172 | DOI: 10.36290/der.2017.033

Treatment of hidradenitis suppurativa

MUDr. Veronika Slonková, Ph.D.
I. dermatovenerologická klinika FN u sv. Anny a LF MU v Brně

Hidradenitis suppurativa (HS) is a chronic recurrent inflammatory disease characterized by deep painful nodules, abscesses,sinus tracts and scarring. The most common areas affected are the axillae, the groin, the buttocks, the anogenital and perinealregion, inframammary areas. Its pathogenesis is multifactorial and includes genetic aspects, immune dysregulation, smokingand obesity. The treatment of HS depends on the severity of the disease (according to Hurley classification) and on its activity(according to Physician´s Global Assessment). First-line treatment includes topical clindamycin, oral doxycyclin or oral clindamycinand adalimumab. Surgical treatment includes deroofing, incision of inflammatory lesions, reconstruction with flap plasty, carbondioxide laser therapy, Nd:YAG laser, total excision of the lesions and surrounding hair-bearing skin and second intention healing.

Keywords: hidradenitis suppurativa, treatment, adalimumab

Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slonková V. Treatment of hidradenitis suppurativa. Dermatol. praxi. 2017;11(4):170-172. doi: 10.36290/der.2017.033.
Download citation

References

  1. Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29: 619-644. Go to original source... Go to PubMed...
  2. Martorell A, García-Martínez FJ, Jiménez-Gallo D, et al. An update on hidradenitis suppurativa (Part I). Epidemiology, clinical Aspects, and definition of disease severity. Actas Dermosifiliogr 2015. http://dx.doi.org/10.1016/j.ad.2015.06.004 Go to original source...
  3. Wang B, Yang W, Wen W, et al. Gamma-secretase gene mutations in familial acne inversa. Science 2010; 330: 1065. Go to original source... Go to PubMed...
  4. Sabat, et al. Increased prevalence of metabolic syndrome in patients with acne inversa. PLoS One 2012; 7: e31810. Go to original source... Go to PubMed...
  5. von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Venereol 2000; 14: 389-392. Go to original source... Go to PubMed...
  6. Gulliver W, Zouboulis CC, Prens E, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa, Rev Endocr Metab Disord DOI 10.1007/s11154-016-9328-5.
  7. Arenbergerova M, Gkalpakiotis S, Arenberger P. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy. Int J Dermatol 2010; 49(12): 1445-1449. Go to original source... Go to PubMed...
  8. Matusiak L, Bieniek A, Szepietowski JC. Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients. Br J Dermatol 2014; 171: 170-174. Go to original source... Go to PubMed...
  9. Ingram JR, Woo PN, Chua SL, et al. Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol 2016; 174: 970-978. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.